RARE News and Press, Ultragenyx Pharmaceutical Inc.

2024-06-30 09:25:12 ET Summary Mereo BioPharma Group plc has seen a rebound in its stock over the past year, with positive analyst commentary in the second quarter. The company is focused on developing therapeutics for oncology and rare diseases, with a lead candidate for Osteogen...

2024-06-14 05:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-14 04:45:04 ET More on Ultragenyx Pharmaceutical Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching Ultragenyx to file for accelerated approval of rare metabolic disease candidate Mereo spikes after mid-stage data for Ultragenyx-part...

2024-06-12 16:40:12 ET More on Ultragenyx Pharmaceutical Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy Ultragenyx upped at Goldman Sachs on bone disorder t...

NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that it has commenced an underwritten p...

Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear sufficient for a biologics license application (BLA) submission NOVATO, Calif., June ...

2024-06-12 07:00:18 ET More on Mereo BioPharma, Ultragenyx, etc. Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript Mereo BioPharma's Pipeline Promise Vs. Valuation And ...

14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment resulted in continued, substantial improvements in bone mineral density (BMD) with a me...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

2024-06-06 15:42:20 ET Summary Ultragenyx Pharmaceutical Inc. revenues from regulatory approved drugs in Q1 of 2024 were $109 million, representing sales growth of 8% compared to the same time period in 2023. Setrusumab is an anti-sclerostin monoclonal antibody being developed for...